University of New South Wales (UNSW) researchers are running two new studies on hepatitis C, which could revolutionise treatment for the virus.

It is hoped that one study could lead to cure rates of almost 100 percent in those who have just been infected with the virus. The US-funded Australian Trial in Acute Hepatitis C (ATAHC) study involves giving people the drug Pegylated interferon within six months of being diagnosed.

"There is good news and bad news with this virus," said Associate Professor Dore. "We can cure 50-80 percent of people with current treatments and are working on new ways of administering drugs to improve these rates further, but on the other hand, there is not a lot of awareness about this amongst people with hepatitis C or GPs."

The problem is that most Hepatitis C patients come to know about their disease when it has advanced. Dialysis patients are very much at risk for Hepatitis C. So far the accepted treatment has been a dual therapy with Interferon and Ribavarin, earlier the better.

Source